New IV Facility as per US FDA and EU guidelines set up in December 2006.
This facility is able to manufacture vials ranging from 10 ml - 500ml

Indian Pharmaceutical market has exhibited a growth of about 15% in the past four years. This is in contrast to the World Pharmaceutical Market, where the major developed markets are progressing sluggishly at 5.2%. Domestic business has contributed significantly to this robust growth. As the Indian Pharmaceutical market heads into the new decade – the feeling is upbeat and the projections are healthy. We at J. B. Chemical & Pharmaceuticals Ltd. are a part of this mission.

J. B. Chemical & Pharmaceuticals Ltd. distributes its products to doctors and millions of users across India through a penetrative strong network of over 2,500 distributors and dealers. Who redistribute to more than 3 lacs retailers in the domestic market.

J. B. Chemical & Pharmaceuticals Ltd.'s operations in CIS countries, makes it a strong Indian Multinational with its powerful marketing tie ups in many countries.

The Past

JBCPL today in domestic market is ranked 37th having 0.53% market share with sales of about Rs. 245 crore. JBCPL distributes its products to doctors and millions of users across lndia through a penetrative strong network of over 2500 distributors and dealers.

More than 600 committed marketing professionals faithfully maintain over 1,00,000 monthly contacts with doctors all over the country. Imbibed with the strength of precision, perfection, efficiency and accuracy JBCPL has a plethora of 11 manufacturing facilities in four exquisite locations of Ankleshwar, Belapur, Daman and Panoli.

JBCPL has a strong presence in various therapeutic segments that includes life style management therapy such as cardio vascular drugs & anti ulcerants and acute therapy such as pain management & anti infectives. JBCPL enjoys a brand leadership status in most of these segments with its brands amongst the top ranks in their categories.


The Present

JBCPL understands the market dynamics and is providing tailor made solutions to therapeutic challenges faced by Physicians. Keeping in tune with this philosophy, JBCPL has further strengthened its presence in Domestic market.

In the life style and cardiovascular category JBCPL has shown an impressive performance with its flagship brand Nicardia Retard fighting the battle against an onslaught of new generation anti-hypertensives. Moreover, JBCPL has evolved Cilacar, a new generation calcium channel blocker which is gaining market share on month-to-month basis. This has helped JBCPL to grab 7% market share with both Nicardia Retard and Cilacar.

Moreover, JBCPL has enriched its Pain, Anti-infective, Gastro therapeutic segments by introducing new molecules.


The Future

There are multitude of opportunities and ways to surge ahead! JBCPL is committed to make the right choices to move forward through speciality focus and introduction of new molecules in Cardiovascular, Gastroenterology, Gynaecology, Dental care, Anti-infective and pain management category. Moreover, JBCPL is also committed to increase its penetration in semi-rural and rural markets with dedicated field force.

Copyright © 2005 J. B. Chemicals & Pharmaceuticals Ltd. All rights reserved.